rs57137919 — ABCG1

ABCG1 promoter variant that reduces transporter expression, impairing macrophage cholesterol efflux and increasing macrophage apoptosis — yet paradoxically associated with higher HDL-C, lower LDL-C, and reduced coronary artery disease risk in population studies

See your personal result for ABCG1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ABCG1 rs57137919 — The Promoter Variant That Rewrites the Macrophage–Cholesterol Equation

Deep inside arterial walls, macrophages perform one of the most critical housekeeping tasks in cardiovascular biology: absorbing excess cholesterol from the surrounding tissue and offloading it to high-density lipoprotein (HDL) particles for return to the liver. This reverse cholesterol transport pathway — the body's primary mechanism for clearing arterial cholesterol — depends on the ABCG1 transporter11 ABCG1 transporter
ATP-binding cassette subfamily G member 1, a membrane protein that pumps cholesterol and phospholipids from macrophage cell membranes onto mature HDL particles. When ABCG1 is disrupted, macrophages loaded with cholesterol cannot offload their cargo efficiently. They accumulate cholesterol, become foam cells, undergo accelerated apoptosis, and contribute to the necrotic core of atherosclerotic plaques.

The rs57137919 variant sits in the promoter region of ABCG1 (described as -367G>A in the original literature, consistent with its position upstream of key ABCG1 transcripts on chromosome 21). The G allele at this position is the GRCh38 reference and the population-major allele (~86% globally). It is associated with higher CAD risk in population studies — not because G is pathogenic, but because the less-common A allele confers protection through mechanisms that appear to dominate the macrophage impairment seen in cell studies.

The Mechanism

The rs57137919 G>A substitution reduces the ability of regulatory proteins to bind the ABCG1 promoter region. Luciferase reporter assays22 Luciferase reporter assays confirmed that the A allele impairs promoter-driven transcription, leading to lower ABCG1 mRNA and protein expression in macrophages. At the cellular level, this has measurable consequences: macrophages from A/A donors show 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in cholesterol-induced apoptosis33 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in cholesterol-induced apoptosis compared to G/G macrophages, with significant upregulation of the pro-apoptotic genes Bok and Bid.

Yet at the population level, A allele carriers have better cardiovascular outcomes. The most likely explanation is that ABCG1 also regulates systemic lipoprotein metabolism in ways that benefit the overall lipid profile: A allele carriers show higher HDL-C and lower LDL-C in multiple Chinese cohort studies. The net effect — better circulating lipid profile — appears to outweigh the macrophage-level efflux impairment in population cardiovascular endpoints. This makes rs57137919 a compelling example of how a single variant can have opposing biological effects at the cellular and systemic levels simultaneously.

The Evidence

The foundational study is Xu et al. 2011 (Atherosclerosis)44 Xu et al. 2011 (Atherosclerosis), a case-control study of 1,021 CAD patients and 1,013 controls in a Chinese Han population. A allele carriers had an adjusted OR of 0.73 (p=0.033) for CAD and 0.65 (p=0.014) for myocardial infarction. Among those with CAD, A allele carriers showed less severe angiographic disease (multi-vessel vs single-vessel OR=0.40, p=0.005). The same study confirmed with luciferase assays that the A allele reduces ABCG1 promoter function, establishing the functional basis for the observed association.

The mechanistic detail was expanded by Liu et al. 2014 (PLoS One)55 Liu et al. 2014 (PLoS One), which isolated macrophages from human donors stratified by rs57137919 genotype and measured cholesterol efflux and apoptosis directly. G/G macrophages showed the highest efflux capacity; A/A macrophages showed 23% lower efflux and twice the rate of apoptosis when loaded with cholesterol. This cellular impairment is real and biologically significant — it would be expected to accelerate plaque formation in isolation.

On lipid profiles, Wang et al. 2020 (Ann Vasc Surg)66 Wang et al. 2020 (Ann Vasc Surg) documented that GA and AA carriers have significantly higher HDL-C (p=0.021) and lower LDL-C (p=0.017) than GG individuals in a Chinese Han cohort. The connection to stroke was confirmed by Yang et al. 2022 (Gene)77 Yang et al. 2022 (Gene) — the AA genotype was significantly less common in stroke patients (4.6% vs 13.3% in controls, p=0.030) and associated with the lowest LDL-C levels. In Li et al. 201588 Li et al. 2015, the protective effect was particularly evident in hypertriglyceridemic subjects.

Note that all published studies to date have been conducted in East Asian populations (primarily Chinese Han), which limits direct generalizability to European or African ancestry groups. The biological mechanism is expected to be conserved, but effect sizes in other populations require separate study.

Practical Actions

For GG homozygotes (~74% of people globally): ABCG1 is expressed at full baseline levels in macrophages — reverse cholesterol transport operates without the promoter impairment carried by A allele carriers. The trade-off is that population studies show GG individuals have modestly higher CAD and stroke risk compared to A carriers, driven by less favorable average lipid profiles (lower HDL-C, higher LDL-C). Supporting ABCG1 function and HDL-mediated cholesterol clearance through targeted dietary and lifestyle choices is worthwhile.

For GA heterozygotes (~24%): one A allele partially reduces ABCG1 expression, producing an intermediate effect on both macrophage efflux and lipid profile. HDL-C tends to be mildly higher and LDL-C modestly lower than GG. Monitoring the lipid profile — especially HDL-C and triglycerides together — gives a more complete picture.

For AA homozygotes (~2%): two A alleles produce the largest reduction in ABCG1 expression, the most impaired macrophage cholesterol efflux, and the greatest elevation of macrophage apoptosis. Paradoxically, these individuals also tend to have the most favorable circulating lipid profiles (highest HDL-C, lowest LDL-C) and show the greatest population-level protection from CAD and stroke. The cellular-level macrophage impairment is real and may become clinically relevant under conditions of high dietary cholesterol or pro-inflammatory stress that overwhelms the protective lipid profile advantage.

Interactions

ABCG1 works in concert with ABCA1 in macrophage cholesterol efflux — ABCA1 mediates initial transfer of cholesterol to lipid-poor apoA-I (forming nascent HDL), while ABCG1 loads cholesterol onto mature spherical HDL particles. Variants in ABCA1 (rs4149338) have been studied alongside rs57137919 in stroke research, with opposing directions: ABCA1 variants associated with increased stroke risk while ABCG1 rs57137919 A allele showed protection. The combined effect of ABCG1 and ABCA1 variants on macrophage cholesterol efflux capacity is a candidate for compound action, given that both transporters act sequentially in the same pathway.

The protective effect of the A allele is particularly pronounced in hypertriglyceridemic individuals (Li et al. 2015), suggesting the rs57137919 effect may interact with triglyceride metabolism. ABCG1 participates in VLDL processing and lipoprotein particle remodeling, providing a mechanistic link between this promoter variant and triglyceride pathways — placing it at the intersection of macrophage biology and fatty acid metabolism.

Nutrient Interactions

cholesterol altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Full ABCG1 Expression Normal

Full ABCG1 expression in macrophages; population studies show modestly higher cardiovascular risk compared to A allele carriers

The paradox of the GG genotype is that full ABCG1 expression — which would seem optimal for macrophage cholesterol efflux and reverse cholesterol transport — does not translate into the best cardiovascular outcomes at the population level. The Xu et al. 2011 study found that GG individuals had higher rates of multi-vessel CAD and myocardial infarction compared to A allele carriers, with the A allele showing an adjusted OR of 0.73 for overall CAD (p=0.033) and 0.65 for MI (p=0.014). This likely reflects the broader lipid effects of ABCG1 on HDL and LDL metabolism, which favor A allele carriers at the systemic level.

GG individuals may benefit from dietary strategies that actively support HDL function and reduce LDL-C, since their lipid profile tends to be less favorable than A allele carriers on average. The higher HDL-C seen in A carriers is partly driven by ABCG1's role in VLDL/HDL remodeling beyond just macrophage efflux.

Studies have primarily been conducted in East Asian populations; the quantitative CAD risk differences may not translate exactly to European or other populations, though the biological mechanism is likely conserved.

AA Low ABCG1 Expression Beneficial

Two A alleles substantially reduce ABCG1 expression — macrophage efflux is impaired but population studies show significant protection from coronary artery disease and stroke

The AA genotype represents a genuine tension between cellular mechanism and population-level outcome. At the molecular level, the Liu et al. 2014 mechanistic study demonstrated that macrophages from AA donors showed 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in apoptosis when loaded with cholesterol, along with significant upregulation of pro-apoptotic genes Bok and Bid. This would be expected to accelerate plaque necrotic core formation in isolation.

But at the population level, the Xu et al. 2011 study (n=2,034) found AA carriers had the lowest CAD rates, with the A allele showing adjusted OR=0.73 for CAD and 0.65 for MI. Yang et al. 2022 found AA genotype in only 4.6% of stroke patients vs 13.3% of controls (p=0.030). The Yang et al. study also linked AA to the lowest LDL-C levels in the cohort. Wang et al. 2020 confirmed GA and AA carriers have higher HDL-C (p=0.021) and lower LDL-C (p=0.017) than GG homozygotes.

The simplest reconciliation is that ABCG1's role in systemic lipoprotein metabolism — particularly in HDL maturation and VLDL remodeling — produces a net favorable lipid shift in A allele carriers that is large enough to offset the macrophage efflux impairment at the population level. The macrophage impairment may still matter under conditions of high cholesterol load, severe hypertriglyceridemia, or systemic inflammation, where the lipid profile advantage is overwhelmed.

Li et al. 2015 specifically showed the protective association was strongest in the hypertriglyceridemic subgroup, suggesting context-dependent expression of the A allele's benefit. Note that all published data are from East Asian (primarily Chinese Han) populations; quantitative risk estimates may differ in European or other ancestry groups.

AG Reduced ABCG1 Expression Intermediate

One A allele reduces ABCG1 promoter activity — modestly lower macrophage cholesterol efflux with a somewhat improved lipid profile

The AG heterozygote sits between two phenotypes. At the cellular level, partial reduction in ABCG1 expression leads to intermediate macrophage cholesterol efflux — less efficient than GG but better than AA. At the systemic level, the lipid profile is intermediate too: modestly higher HDL-C and lower LDL-C than GG, but less pronounced than in AA homozygotes.

The Xu et al. 2011 case-control study showed that A allele carriers (pooled GA + AA) had significantly lower CAD risk than GG individuals. The Wang et al. 2020 study confirmed that both GA and AA carriers show higher HDL-C and lower LDL-C compared to GG. These lipid advantages appear to be mediated through ABCG1's broader role in lipoprotein remodeling beyond macrophage-specific efflux.

Monitoring the lipid profile alongside any inflammatory markers (hsCRP) is informative, as the macrophage efflux impairment from reduced ABCG1 expression may become more relevant when systemic inflammation is elevated.